

EAACI Congress 2024

Valencia, Spain

31 May - 3 June



Revolutionising Patient Care
Through the Power of Data Science



#EAACIcongress

www.eaaci.org



Abstract Prize Winners

Oral Abstracts Sessions
(OAS)

&

Oral Abstracts on Clinical Trials
(OAS-CT)

Presenter	Session	number	Title	Abstract ID
Jelena Janković	Advances in Allergen Immunotherapy	OAS 1	Effect of allergen specific immunotherapy on PFS symptoms	001971
Francesco Foppiano Florez Estrada	Insights into Asthma: from childhood origins to adult outcome	OAS 2	Differential gene expression analysis in ten year old asthmatic children from the PASTURE cohort	000614
Victor Higgs	Advances in pediatric asthma: predictors, diagnostics, and immunological insights	OAS 3	Diagnosing Asthma with an Exhaled Breath Test at the Point of Care (POC)	001728
Angel Maldonado	Emerging insights in immunomodulation and allergic responses	OAS 4	Cannabinoids exert tolerogenic properties in DCs via epigenetic remodeling and extracellular vesicle secretion with the capacity to polarize Tregs	001464
Nuria Contreras	Novelties in asthma Biomarkers and immunomodulatory pathways	OAS 5	Multi-omic analyses reveal new potential biomarkers for monitoring asthmatic patients treated with either Mepolizumab or Omalizumab	001291
Pedro Morais Silva	Frontiers in Allergen Immunotherapy: evidence from clinical trials	OAS 6	Predicting clinical response to allergen-specific immunotherapy to D. pteronyssinus using serological pre-treatment parameters	001792
Yael Koren	Advances in Oral Immunotherapy	OAS 7	Oral immunotherapy (OIT) in walnut and hazelnut co-allergic patients: ELISA inhibition studies to direct treatment approach	001550
Elisa Sánchez Martínez	Innovations in Food Allergy Immunotherapy	OAS 8	Allergen metabolism by human oral bacteria alters its allergenicity	000764
Rubén G. Gordo	Emerging insights into food allergy mechanisms and clinical management	OAS 9	Butyrate-Mediated Sin a 1 Nuclear Translocation in Food Allergy Development	000662
Marcus Maurer	Advances in Chronic Urticaria treatment	OAS 10	Rilzabrutinib Results in Rapid Improvement of Symptoms in Patients With Chronic Spontaneous Urticaria: Results From the RILECSU Phase 2 Dose-Ranging Study	000705

Presenter	Session	number	Title	Abstract ID
Marie Bodinier	Epidemiology of allergy	OAS 11	Prenatal maternal supplementation with prebiotics regulates microbiota colonization in high-risk children, but do not prevent atopic dermatitis at one year of age	000091
Raffaella Campana	Insights into allergy Cross-reactions and diagnostic challenges	OAS 12	IgE-sensitisation profile to peanut allergen components: reassessment of the prevalence and patterns on a global scale	001087
Jane Wong	Advances in drug allergy diagnosis and management	OAS 13	Head-to-head comparison between allergist vs. non-allergist in low risk penicillin allergy delabelling: effectiveness, safety and impact on quality of life from a multi-centre, prospective cohort study in Hong Kong (HK-DADI2)	001073
Anand Kumar Andiappan	Epithelial Barriers: insights into function and dysfunction	OAS 14	Untargeted proteomics identifies key inflammation and barrier dysfunction networks defining a unique signature for Asian Atopic Dermatitis (AAD)	001000
Daniel Lozano-Ojalvo	Advancing Atopic Dermatitis care: insights and innovations	OAS 15	Treatment of atopic dermatitis patients with dupilumab restores functional responses of circulating skin-homing CD4+ T and B cells	001838
Alexis Bocquet	Insights into Hereditary Angioedema management	OAS 16	Impact of hereditary angioedema on dental care: from a study of 112 French patients	000326
Laura Hesselberg	Novel aspects on pediatric allergy	OAS 17	Sex differences in childhood asthma are driven by a T2-high phenotype and mediated through sex-hormone metabolites	000616
Mohammadmilad Ameri	Anaphylaxis and drug allergy	OAS 18	Drug Reaction With Eosinophilia and Systemic Symptoms: Deciphering the diversity of systemic immune profiles	100213
Ankur Jindal	Breakthroughs in management of Hereditary Angioedema	OAS 19	Clinical profile and management of pediatric hereditary angioedema in resource constrained settings: our experience from a single centre in North India	001739
Sumeyra Alan Yalim	Targeting the environment in allergy	OAS 20	Evaluation of Air Pollution in Terms of Oxidant – Antioxidant Balance and Airway Sensitivity in Rhinitis Patients	001613

Presenter	Session	number	Title	Abstract ID
shweta agarwal	Advances in Ocular allergy	OAS 21	New grading of Vernal keratoconjunctivitis based on clinical profile of 1049 Vernal Keratoconjunctivitis patients	000259
Oded Shamriz	Novel insights into Biomarkers	OAS 22	Deciphering the Clinical Significance of Very-High IgE Levels (≥ 1000 U/mL) Among Adult Patients: a Population-based Study of 283,406 Subjects	001053
Xin Feng	Understanding and managing Chronic Rhinosinusitis with Nasal Polyps	OAS 23	Bimin Kang ameliorates the minimal persistent inflammation in allergic rhinitis by reducing BCL11B expression and regulating ILC2 plasticity	001085
Kaylee Sohng	Challenges in Anaphylaxis management	OAS 24	Association of lipid-lowering medications and Hymenoptera venom anaphylaxis severity: a multi-centre study	000854
Michiel Beyens	Cuting edge mastocytosis: genetics, burden, and therapeutic	OAS 25	Prevalence of drug-induced anaphylaxis low among 470 patients with mastocytosis - A two-center retrospective study	000554
Julia Eckl-Dorna	Challenges in Biologics for Chronic Rhinosinusitis with Nasal Polyps	OAS 26	Dupilumab treatment effectively reduces nasal type 2 cytokine production following acetylsalicylic acid provocation in N-ERD patients	001333
Dragan Mijakoski	Challenges in occupational and environmental allergy	OAS 27	Researcher mental health in allergy departments: implementation of Researcher Mental Health Observatory (ReMO) recommendations	000904
Miriam Leskien	Lessons from birth cohort investigations	OAS 28	Childhood asthma and allergy is related to accelerated epigenetic aging in the LISA birth cohort	000467
Aila Fakhimahmadi	Innovations in allergy: insights from dietary interventions and immunomodulation	OAS 29	Reduced allergenicity of the mold major allergen Alt a 1 when iron is sufficient: implications in nutritional immunity and immune resilience	001891
Caitlin Burk	Breakthroughs in Eosinophilic Esophagitis	OAS 30	Expression of GPR15 and CD38 on peripheral blood pathogenic effector Th2 cells can identify active eosinophilic esophagitis	002022

Presenter	Session	number	Title	Abstract ID
Silvia Sánchez Herrero	Advances in Immunotherapy	L-OAS 1	Purified free mannan promotes tolerogenic responses in peanut-stimulated human dendritic cells	100114
Antonino Marcello Pilia	Managing Skin Allergies: Urticaria, Dermatitis, and Angioedema	L-OAS 2	Omalizumab and chronic spontaneous urticaria: 'one dose does not fit all'	100246
Jessica O'Konek	Advances in Food Allergy & Mucosal Immunity	L-OAS 3	Mucosal delivery of allergen-specific immunotherapy with vaccine adjuvants suppresses allergic disease through both humoral and cellular immune mechanisms	100273
Hanya Ahmed	New Frontiers in Respiratory Allergy	L-OAS 4	Advancing Asthma Diagnosis: Integrating Exhaled Biomarkers and Deep Neural Networks (DNNs) in a POC Breath Test	100067
Danijela Apostolic	Nanoplastics and Barrier Function: Implications for Allergic Responses	L-OAS 5	Binding of food allergens to nanoplastics and their effect on allergic responses	100095
Mohammed Zghaebi	Unraveling Allergic Mechanisms	L-OAS 6	IgE repertoire analysis identifies shared interpatient and inpatient IgE clones in birch pollen-allergic subjects	100361
Davide Caimmi	Clinical trials on Asthma and Rhinitis	OAS-CT01	The SQ HDM SLIT-tablet is effective and well-tolerated in children (5-11 years) with house dust mite allergic rhinitis/rhinoconjunctivitis with and without concomitant asthma – results from a global phase III clinical trial	001124
Marcus Maurer	Clinical trials	OAS-CT02	Barzolvolimab Significantly Improves Angioedema in Patients with Chronic Spontaneous Urticaria (CSU): Results from a Phase 2 Trial	000228
Danny M. Cohn	Clinical trials	L-OAS-CT 01	Donidalorsen for the treatment of hereditary angioedema: Results from a phase 3, randomised, placebo-controlled trial	100099